www.fdanews.com/articles/197591-regeneron-begins-clinical-trials-of-covid-19-antibody-cocktail
Regeneron Begins Clinical Trials of COVID-19 Antibody Cocktail
June 12, 2020
Regeneron has begun the first clinical trial of its investigational COVID-19 antibody cocktail REGN-COV2 for the prevention and treatment of COVID-19.
The set of trials it plans to undertake consists of four separate populations: hospitalized patients, nonhospitalized patients, uninfected individuals in groups at high-risk of exposure and uninfected individuals with close exposure to a COVID-19 patient.
Regeneron said it is scaling production to have hundreds of thousands of preventative doses or tens of thousands of larger treatment doses per month by the end of August.